 AstraZeneca plc NASDAQ: AZN and Daiichi Sankyo Co Ltd OTC: DSKYF have announced high-level results from the head-to-head DESTINY-Breast03 Phase 3 trial of Enhertu. The trial reached its primary endpoint in a study including HER2-positive metastatic breast cancer patients who had previously been treated with one prior line of HER2-based therapy. 